Skip to main content
Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology 4/2007

01.04.2007 | Clinical Investigation

Transscleral local resection versus iodine brachytherapy for uveal melanomas that are large because of tumour height

verfasst von: Ilkka Puusaari, Bertil Damato, Tero Kivelä

Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology | Ausgabe 4/2007

Einloggen, um Zugang zu erhalten

Abstract

Background

To compare visual outcome and ocular complications of transscleral local resection (TSR) with those of iodine-125 plaque brachytherapy (IBT) for uveal melanomas categorised as large because of tumour height.

Methods

Retrospective study of 87 patients with a uveal melanoma ≤16 mm by largest basal diameter (median, 12.6 vs 14.0 mm for TSR and IBT, respectively) and large by height (median, 11.0 vs 10.6 mm) by the Collaborative Ocular Melanoma Study (COMS) criteria. Thirty-three patients underwent TSR in the United Kingdom and 54 underwent IBT in Finland. Loss of 20/65 and 20/400 vision, local tumour recurrence, cataract, iris neovascularization, glaucoma, maculopathy, optic neuropathy, persistent retinal detachment, and vitreous haemorrhage were analysed using competing risks and logistic regression to control for confounders.

Results

All patients save one managed with TSR lost 20/70 vision within 3 years. The 2-year cumulative incidence of losing 20/400 vision was 60% (95% CI, 35–75) for TSR and 75% (95% CI, 59–86) for IBT. The 5-year incidence of local tumour recurrence was 41% (95% CI, 17–63) after TSR and 7% (95% CI, 2–17) after IBT. Glaucoma and optic neuropathy were rare after TSR. Cataract, maculopathy, retinal detachment, and vitreous haemorrhage were common after either treatment. The number of patients needed to treat with TSR instead of IBT was four for one additional patient to benefit by avoiding loss of visual acuity 20/400 for at least 2 years, and the corresponding number was three for one additional patient to experience a local recurrence from TSR.

Conclusions

If TSR is further evaluated as an alternative to IBT in avoiding blindness of an eye with a ciliochoroidal melanoma categorised as large by COMS criteria because of its height, special emphasis must be given to increased risk of local tumour recurrence.
Literatur
1.
Zurück zum Zitat Altman DG (1998) Confidence intervals for the number needed to treat. BMJ 317:1309–1312PubMed Altman DG (1998) Confidence intervals for the number needed to treat. BMJ 317:1309–1312PubMed
2.
Zurück zum Zitat Bechrakis NE, Bornfeld N, Zoller I, Foerster MH (2002) Iodine 125 plaque brachytherapy versus transscleral tumor resection in the treatment of large uveal melanomas. Ophthalmology 109:1855–1861PubMedCrossRef Bechrakis NE, Bornfeld N, Zoller I, Foerster MH (2002) Iodine 125 plaque brachytherapy versus transscleral tumor resection in the treatment of large uveal melanomas. Ophthalmology 109:1855–1861PubMedCrossRef
3.
Zurück zum Zitat Bender R (2001) Calculating confidence intervals for the number needed to treat. Control Clin Trials 22:102–110PubMedCrossRef Bender R (2001) Calculating confidence intervals for the number needed to treat. Control Clin Trials 22:102–110PubMedCrossRef
4.
Zurück zum Zitat Char DH, Bove R, Phillips TL (2003) Laser and proton radiation to reduce uveal melanoma-associated exudative retinal detachments. Am J Ophthalmol 136:180–182PubMedCrossRef Char DH, Bove R, Phillips TL (2003) Laser and proton radiation to reduce uveal melanoma-associated exudative retinal detachments. Am J Ophthalmol 136:180–182PubMedCrossRef
5.
Zurück zum Zitat Char DH, Miller T, Crawford JB (2004) Analysis of melanoma cell type in uveal melanoma following treatment failure. Am J Ophthalmol 138:543–546PubMedCrossRef Char DH, Miller T, Crawford JB (2004) Analysis of melanoma cell type in uveal melanoma following treatment failure. Am J Ophthalmol 138:543–546PubMedCrossRef
6.
Zurück zum Zitat Collaborative Ocular Melanoma Study Group (1998) The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma I: characteristics of patients enrolled and not enrolled. COMS report no. 9. Am J Ophthalmol 125:767–778CrossRef Collaborative Ocular Melanoma Study Group (1998) The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma I: characteristics of patients enrolled and not enrolled. COMS report no. 9. Am J Ophthalmol 125:767–778CrossRef
7.
Zurück zum Zitat Damato B (1997) Adjunctive plaque radiotherapy after local resection of uveal melanoma. Front Radiat Ther Oncol 30:123–132PubMed Damato B (1997) Adjunctive plaque radiotherapy after local resection of uveal melanoma. Front Radiat Ther Oncol 30:123–132PubMed
8.
Zurück zum Zitat Damato B, Groenewald CP, McGalliard JN, Wong D (2002) Rhegmatogenous retinal detachment after transscleral local resection of choroidal melanoma. Ophthalmology 109:2137–2143PubMedCrossRef Damato B, Groenewald CP, McGalliard JN, Wong D (2002) Rhegmatogenous retinal detachment after transscleral local resection of choroidal melanoma. Ophthalmology 109:2137–2143PubMedCrossRef
9.
Zurück zum Zitat Damato B, Lecuona K (2004) Conservation of eyes with choroidal melanoma by a multimodality approach to treatment: an audit of 1632 patients. Ophthalmology 111:977–983PubMedCrossRef Damato B, Lecuona K (2004) Conservation of eyes with choroidal melanoma by a multimodality approach to treatment: an audit of 1632 patients. Ophthalmology 111:977–983PubMedCrossRef
10.
Zurück zum Zitat Damato BE, Paul J, Foulds WS (1993) Predictive factors of visual outcome after local resection of choroidal melanoma. Br J Ophthalmol 77:616–623PubMed Damato BE, Paul J, Foulds WS (1993) Predictive factors of visual outcome after local resection of choroidal melanoma. Br J Ophthalmol 77:616–623PubMed
11.
Zurück zum Zitat Damato BE, Paul J, Foulds WS (1996) Risk factors for residual and recurrent uveal melanoma after trans-scleral local resection. Br J Ophthalmol 80:102–108PubMed Damato BE, Paul J, Foulds WS (1996) Risk factors for residual and recurrent uveal melanoma after trans-scleral local resection. Br J Ophthalmol 80:102–108PubMed
12.
Zurück zum Zitat De Potter P, Shields CL, Shields JA, Cater JR, Brady LW (1996) Plaque radiotherapy for juxtapapillary choroidal melanoma. Visual acuity and survival outcome. Arch Ophthalmol 114:1357–1365PubMed De Potter P, Shields CL, Shields JA, Cater JR, Brady LW (1996) Plaque radiotherapy for juxtapapillary choroidal melanoma. Visual acuity and survival outcome. Arch Ophthalmol 114:1357–1365PubMed
13.
Zurück zum Zitat Detorakis ET, Engstrom RE Jr, Wallace R, Straatsma BR (2005) Iris and anterior chamber angle neovascularization after iodine 125 brachytherapy for uveal melanoma. Ophthalmology 112:505–510PubMedCrossRef Detorakis ET, Engstrom RE Jr, Wallace R, Straatsma BR (2005) Iris and anterior chamber angle neovascularization after iodine 125 brachytherapy for uveal melanoma. Ophthalmology 112:505–510PubMedCrossRef
14.
Zurück zum Zitat Diener-West M, Earle JD, Fine SL, Hawkins BS, Moy CS, Reynolds SM, Schachat AP, Straatsma BR, The Collaborative Ocular Melanoma Study Group. (2001) The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS report no. 18. Arch Ophthalmol 119:969–982PubMed Diener-West M, Earle JD, Fine SL, Hawkins BS, Moy CS, Reynolds SM, Schachat AP, Straatsma BR, The Collaborative Ocular Melanoma Study Group. (2001) The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS report no. 18. Arch Ophthalmol 119:969–982PubMed
15.
Zurück zum Zitat Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496–509CrossRef Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496–509CrossRef
16.
Zurück zum Zitat Gooley TA, Leisenring W, Crowley J, Storer BE (2001) Why Kaplan-Meier fails and cumulative incidence succeeds when estimating failure probabilities in the presence of competing risks. In: Crowley J (eds) Handbook of statistics in clinical oncology. Marcel Dekker, New York, pp 513–523 Gooley TA, Leisenring W, Crowley J, Storer BE (2001) Why Kaplan-Meier fails and cumulative incidence succeeds when estimating failure probabilities in the presence of competing risks. In: Crowley J (eds) Handbook of statistics in clinical oncology. Marcel Dekker, New York, pp 513–523
17.
Zurück zum Zitat Gragoudas ES, Li W, Lane AM, Munzenrider J, Egan KM (1999) Risk factors for radiation maculopathy and papillopathy after intraocular irradiation. Ophthalmology 106:1571–1578PubMedCrossRef Gragoudas ES, Li W, Lane AM, Munzenrider J, Egan KM (1999) Risk factors for radiation maculopathy and papillopathy after intraocular irradiation. Ophthalmology 106:1571–1578PubMedCrossRef
18.
Zurück zum Zitat Gunduz K, Shields CL, Shields JA, Cater J, Freire JE, Brady LW (1999) Plaque radiotherapy of uveal melanoma with predominant ciliary body involvement. Arch Ophthalmol 117:170–177PubMed Gunduz K, Shields CL, Shields JA, Cater J, Freire JE, Brady LW (1999) Plaque radiotherapy of uveal melanoma with predominant ciliary body involvement. Arch Ophthalmol 117:170–177PubMed
19.
Zurück zum Zitat Gunduz K, Shields CL, Shields JA, Cater J, Freire JE, Brady LW (1999) Radiation complications and tumor control after plaque radiotherapy of choroidal melanoma with macular involvement. Am J Ophthalmol 127:579–589PubMedCrossRef Gunduz K, Shields CL, Shields JA, Cater J, Freire JE, Brady LW (1999) Radiation complications and tumor control after plaque radiotherapy of choroidal melanoma with macular involvement. Am J Ophthalmol 127:579–589PubMedCrossRef
20.
Zurück zum Zitat Gunduz K, Shields CL, Shields JA, Cater J, Freire JE, Brady LW (1999) Radiation retinopathy following plaque radiotherapy for posterior uveal melanoma. Arch Ophthalmol 117:609–614PubMed Gunduz K, Shields CL, Shields JA, Cater J, Freire JE, Brady LW (1999) Radiation retinopathy following plaque radiotherapy for posterior uveal melanoma. Arch Ophthalmol 117:609–614PubMed
21.
Zurück zum Zitat Hair JF Jr, Tatham RL, Anderson RE, Black WC (1998) Multivariate data analysis, 5th. Prentice-Hall, Upper Saddle River Hair JF Jr, Tatham RL, Anderson RE, Black WC (1998) Multivariate data analysis, 5th. Prentice-Hall, Upper Saddle River
22.
Zurück zum Zitat Harbour JW, Char DH, Kroll S, Quivey JM, Castro J (1997) Metastatic risk for distinct patterns of postirradiation local recurrence of posterior uveal melanoma. Ophthalmology 104:1785–1792PubMed Harbour JW, Char DH, Kroll S, Quivey JM, Castro J (1997) Metastatic risk for distinct patterns of postirradiation local recurrence of posterior uveal melanoma. Ophthalmology 104:1785–1792PubMed
23.
Zurück zum Zitat Kivelä T, Puusaari I, Damato B (2003) Transscleral resection vs. iodine brachytherapy for choroidal malignant melanomas 6 millimeters or more in thickness: a matched case-control study. Ophthalmology 110:2235–2244PubMedCrossRef Kivelä T, Puusaari I, Damato B (2003) Transscleral resection vs. iodine brachytherapy for choroidal malignant melanomas 6 millimeters or more in thickness: a matched case-control study. Ophthalmology 110:2235–2244PubMedCrossRef
24.
Zurück zum Zitat Kivelä T, Eskelin S, Mäkitie T, Summanen P (2001) Exudative retinal detachment from malignant uveal melanoma: predictors and prognostic significance. Invest Ophthalmol Vis Sci 42:2085–2093PubMed Kivelä T, Eskelin S, Mäkitie T, Summanen P (2001) Exudative retinal detachment from malignant uveal melanoma: predictors and prognostic significance. Invest Ophthalmol Vis Sci 42:2085–2093PubMed
25.
Zurück zum Zitat Melia BM, Abramson DH, Albert DM, Boldt HC, Earle JD, Hanson WF, Montague P, Moy CS, Schachat AP, Simpson ER, Straatsma BR, Vine AK, Weingeist TA, Collaborative Ocular Melanoma Study Group (2001) Collaborative Ocular Melanoma Study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma. I. Visual acuity after 3 years. COMS report no. 16. Ophthalmology 108:348–366PubMedCrossRef Melia BM, Abramson DH, Albert DM, Boldt HC, Earle JD, Hanson WF, Montague P, Moy CS, Schachat AP, Simpson ER, Straatsma BR, Vine AK, Weingeist TA, Collaborative Ocular Melanoma Study Group (2001) Collaborative Ocular Melanoma Study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma. I. Visual acuity after 3 years. COMS report no. 16. Ophthalmology 108:348–366PubMedCrossRef
26.
Zurück zum Zitat Packer S, Stoller S, Lesser ML, Mandel FS, Finger PT (1992) Long-term results of iodine 125 irradiation of uveal melanoma. Ophthalmology 99:767–773PubMed Packer S, Stoller S, Lesser ML, Mandel FS, Finger PT (1992) Long-term results of iodine 125 irradiation of uveal melanoma. Ophthalmology 99:767–773PubMed
27.
Zurück zum Zitat Parmar MKB, Machin D (1995) Survival analysis. A practical approach. Wiley, Chichester Parmar MKB, Machin D (1995) Survival analysis. A practical approach. Wiley, Chichester
28.
Zurück zum Zitat Puusaari I, Heikkonen J, Kivela T (2004) Effect of radiation dose on ocular complications after iodine brachytherapy for large uveal melanoma: empirical data and simulation of collimating plaques. Invest Ophthalmol Vis Sci 45:3425–3434PubMedCrossRef Puusaari I, Heikkonen J, Kivela T (2004) Effect of radiation dose on ocular complications after iodine brachytherapy for large uveal melanoma: empirical data and simulation of collimating plaques. Invest Ophthalmol Vis Sci 45:3425–3434PubMedCrossRef
29.
Zurück zum Zitat Puusaari I, Heikkonen J, Kivela T (2004) Ocular complications after iodine brachytherapy for large uveal melanomas. Ophthalmology 111:1768–1777PubMedCrossRef Puusaari I, Heikkonen J, Kivela T (2004) Ocular complications after iodine brachytherapy for large uveal melanomas. Ophthalmology 111:1768–1777PubMedCrossRef
30.
Zurück zum Zitat Puusaari I, Heikkonen J, Summanen P, Tarkkanen A, Kivelä T (2003) Iodine brachytherapy as an alternative to enucleation for large uveal melanomas. Ophthalmology 110:2223–2234PubMedCrossRef Puusaari I, Heikkonen J, Summanen P, Tarkkanen A, Kivelä T (2003) Iodine brachytherapy as an alternative to enucleation for large uveal melanomas. Ophthalmology 110:2223–2234PubMedCrossRef
31.
Zurück zum Zitat Shields CL, Naseripour M, Cater J, Shields JA, Demirci H, Youseff A, Freire J (2002) Plaque radiotherapy for large posterior uveal melanomas (> or=8-mm thick) in 354 consecutive patients. Ophthalmology 109:1838–1849PubMedCrossRef Shields CL, Naseripour M, Cater J, Shields JA, Demirci H, Youseff A, Freire J (2002) Plaque radiotherapy for large posterior uveal melanomas (> or=8-mm thick) in 354 consecutive patients. Ophthalmology 109:1838–1849PubMedCrossRef
32.
Zurück zum Zitat Shields CL, Shields JA, Cater J, Gunduz K, Miyamoto C, Micaily B, Brady LW (2000) Plaque radiotherapy for uveal melanoma: long-term visual outcome in 1106 consecutive patients. Arch Ophthalmol 118:1219–1228PubMed Shields CL, Shields JA, Cater J, Gunduz K, Miyamoto C, Micaily B, Brady LW (2000) Plaque radiotherapy for uveal melanoma: long-term visual outcome in 1106 consecutive patients. Arch Ophthalmol 118:1219–1228PubMed
33.
Zurück zum Zitat Therneau TM, Grambsch PM (2000) Modeling survival data: extending the Cox model. Springer, New York Therneau TM, Grambsch PM (2000) Modeling survival data: extending the Cox model. Springer, New York
Metadaten
Titel
Transscleral local resection versus iodine brachytherapy for uveal melanomas that are large because of tumour height
verfasst von
Ilkka Puusaari
Bertil Damato
Tero Kivelä
Publikationsdatum
01.04.2007
Verlag
Springer-Verlag
Erschienen in
Graefe's Archive for Clinical and Experimental Ophthalmology / Ausgabe 4/2007
Print ISSN: 0721-832X
Elektronische ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-006-0461-9

Weitere Artikel der Ausgabe 4/2007

Graefe's Archive for Clinical and Experimental Ophthalmology 4/2007 Zur Ausgabe

Announcements

Announcements

Neu im Fachgebiet Augenheilkunde

Metastase in der periokulären Region

Metastasen Leitthema

Orbitale und periokuläre metastatische Tumoren galten früher als sehr selten. Aber mit der ständigen Aktualisierung von Medikamenten und Nachweismethoden für die Krebsbehandlung werden neue Chemotherapien und Strahlenbehandlungen eingesetzt. Die …

Staging und Systemtherapie bei okulären und periokulären Metastasen

Metastasen Leitthema

Metastasen bösartiger Erkrankungen sind die häufigsten Tumoren, die im Auge diagnostiziert werden. Sie treten bei ungefähr 5–10 % der Patienten mit soliden Tumoren im Verlauf der Erkrankung auf. Besonders häufig sind diese beim Mammakarzinom und …

Wundheilung nach Trabekulektomie

Trabekulektomie CME-Artikel

Die überschießende Wundheilung in der filtrierenden Glaukomchirurgie ist ein zentraler Faktor für ein operatives Versagen. Nach der Einführung der Trabekulektomie in den 1960er-Jahren wurden viele Faktoren erkannt, die mit einer vermehrten …

„standard operating procedures“ (SOP) – Vorschlag zum therapeutischen Management bei periokulären sowie intraokulären Metastasen

Metastasen Leitthema

Peri- sowie intraokuläre Metastasen sind insgesamt gesehen selten und meist Zeichen einer fortgeschrittenen primären Tumorerkrankung. Die Therapie ist daher zumeist palliativ und selten kurativ. Zudem ist die Therapiefindung sehr individuell. Die …

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.